About

A seasoned team experienced in developing cancer medicines to create a fully integrated oncology company.

PRT2527, a Novel Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor,Has Potent Antitumor Activity in Combination with BTK and BCL2 Inhibition in Various Lymphoid Malignancies

Norman Fultang, Ashley Schwab, Sophia McAneny-Droz, Diane Heiser, Peggy Scherle, Neha Bhagwat